文献速递生殖医学

第7天囊胚究竟有多慢?通过人工智能标准化全面描绘第7天囊胚及其临床价值

How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究纳入意大利一家私立IVF中心2013年1月至2020年12月间681例患者的1966枚囊胚,按活检时间分组分析第7天囊胚的临床价值。若将胚胎培养截止于授精后144小时,获得整倍体囊胚和活产的患者数将分别相对减少7.3%和4.4%。第7天囊胚整倍体率较低源于形态较差和卵母细胞年龄较大,而非发育慢本身;调整混杂后活产率仍显著降低,但以144小时为界时无显著差异。

要点

  • 14.6%的囊胚在授精后144小时之后才达到完全扩张。
  • 第7天囊胚整倍体率较低源于形态差和卵母细胞年龄大,非发育慢本身。
  • 以144小时为截止,获得整倍体囊胚和活产的患者数分别相对减少7.3%和4.4%。

核心结论

  • 将胚胎培养截止于授精后144小时(即6天)会使获得整倍体囊胚和活产的患者数分别相对减少7.3%和4.4%。
  • 第7天囊胚整倍体率较低源于形态较差和卵母细胞年龄较大,而非发育慢本身;调整混杂后活产率仍显著降低,但以144小时为界时无显著差异。

研究设计与样本

  • 观察性研究,纳入2013年1月至2020年12月在意大利一家私立IVF中心时差培养箱中培养的681例患者的1966枚囊胚。
  • 根据意大利法律40/2004,胚胎不依据形态选择,培养至≥168小时为本中心常规。
  • 行ICSI、持续培养且第5天更换培养基、滋养外胚层活检不行辅助孵化,以及全面染色体检测(CCT)诊断完全染色体非嵌合非整倍体。
  • 囊胚按活检时间以12小时间隔分为六组,从<120小时(设为对照)至>168小时。
  • 囊胚质量用Gardner评分评估并用人工智能(AI)软件确认;AI还用于自动标注扩张囊胚时间(tEB)、tEB至完全扩张的小时数、tEB时和活检时囊胚面积及操作时的工作小时。

主要发现

  • 14.6%的囊胚在授精后144小时之后才达到完全扩张(144-156小时范围5.9%,156-168小时范围7.9%,超过168小时0.8%)。
  • 较慢囊胚质量较差(基于胚胎学家和AI评估);较晚的tEB和tEB至完全扩张时间较长均与第7天发育相关,与囊胚质量基本无关。
  • 较慢囊胚活检时略大于较快囊胚,但孵化风险无差异,主要因工作日为此类操作设了两个专用时段。
  • 活检时间132-144小时范围囊胚活产率为36.5%(76/208),对照组(<120小时)为53.0%(114/215),多因素比值比0.61(95%CI 0.40-0.92,校正P=0.02)。
  • 活检时间156-168小时范围囊胚活产率为14.3%(3/21),多因素比值比0.24(95%CI 0.07-0.88,校正P=0.03);以144小时为截止时无显著差异。

临床怎么用

  • 作者认为,在局部法规允许时,选择培养至第7天应基于对夫妇生殖史的仔细评估。
  • 作者认为,患者应知晓第7天囊胚能力低于较快生长的囊胚;但预后差、失败后不太可能再次尝试以及希望生育多个孩子的夫妇可能从中获益。
  • 作者认为,AI工具可帮助提高证据在全球范围内的普遍性。

局限性

  • 未评估妊娠和围产期结局,且缺少成本效益分析。
  • 作者鼓励其他团队在不同培养和活检方案以及不同临床环境和监管背景下探讨此话题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the clinical value of Day 7 blastocysts? SUMMARY ANSWER: Ending embryo culture at 144 hours post-insemination (h.p.i.; i.e. 6 days) would involve 7.3% and 4.4% relative reductions in the number of patients obtaining euploid blastocysts and live birth(s) (LBs), respectively. WHAT IS KNOWN ALREADY: Many studies showed that Day 7 blastocysts are clinically valuable, although less euploid and less competent than faster-growing embryos. Nevertheless, a large variability exists in: (i) the definition of 'Day 7'; (ii) the criteria to culture embryos to Day 7; (iii) the clinical setting; (iv) the local regulation; and/or (v) the culture strategies and incubators. Here, we aimed to iron out these differences and portray Day 7 blastocysts with the lowest possible risk of bias. To this end, we have also adopted an artificial intelligence (AI)-powered software to automatize developmental timings annotations and standardize embryo morphological assessment. STUDY DESIGN, SIZE AND DURATION: Observational study including 1966 blastocysts obtained from 681 patients cultured in a time-lapse incubator between January 2013 and December 2020 at a private Italian IVF center. PARTICIPANTS/MATERIALS, SETTING, METHODS: According to Italian Law 40/2004, embryos were not selected based on their morphology and culture to ≥168 h.p.i. is standard care at our center. ICSI, continuous culture with Day 5 media refresh, trophectoderm biopsy without assisted hatching and comprehensive chromosome testing (CCT) to diagnose full-chromosome non-mosaic aneuploidies, were all performed. Blastocysts were clustered in six groups based on the time of biopsy in h.p.i. at 12 hr intervals starting from <120 h.p.i. (set as control) up to >168 h.p.i. Blastocyst quality was assessed using Gardner's scheme and confirmed with AI-powered software. AI was also used to automatically annotate the time of expanding blastocyst (tEB) and the hours elapsing between this moment and the achievement of full expansion when blastocysts were biopsied and vitrified. Also, blastocyst area at tEB and at the time of biopsy was automatically assessed, as well as the hour of the working day when the procedure was performed. The main outcomes were the euploidy rate and the LB rate (LBR) per vitrified-warmed euploid single blastocyst transfer. The results were adjusted for confounders through multivariate logistic regressions. To increase their generalizability, the main outcomes were reported also based on a 144-h.p.i. cutoff (i.e. 6 exact days from ICSI). Based on this cutoff, all the main patient outcomes (i.e. number of patients obtaining blastocysts, euploid blastocysts, LBs, with supernumerary blastocysts without a LB and with surplus blastocysts after an LB) were also reported versus the standard care (>168 h.p.i.). All hypothetical relative reductions were calculated. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 14.6% of the blastocysts reached full expansion beyond 144 h.p.i. (5.9% in the range 144-156 h.p.i., 7.9% in the range 156-168 h.p.i. and 0.8% beyond 168 h.p.i.). Slower blastocysts were of a worse quality based on the evaluation of both embryologists and AI. Both later tEB and longer time between tEB and full blastocyst expansion concurred to Day 7 development, quite independently of blastocyst quality. Slower growing blastocysts were slightly larger than faster-growing ones at the time of biopsy, but no difference was reported in the risk of hatching, mainly because two dedicated slots have been set along the working day for these procedures. The lower euploidy rate among Day 7 blastocysts is due to their worse morphology and more advanced oocyte age, rather than to a slower development per se. Conversely, the lower LBR was significant even after adjusting for confounders, with a first relevant decrease for blastocysts biopsied in the range 132-144 h.p.i. (N = 76/208, 36.5% versus N = 114/215, 53.0% in the control, multivariate odds ratio 0.61, 95% CI 0.40-0.92, adjusted-P = 0.02), and a second step for blastocysts biopsied in the range 156-168 h.p.i. (N = 3/21, 14.3%, multivariate odds ratio: 0.24, 95% CI 0.07-0.88, adjusted-P = 0.03). Nevertheless, when the cutoff was set at 144 h.p.i., no significant difference was reported. In this patient population, ending embryo culture at 144 h.p.i. would have caused 10.6%, 7.3%, 4.4%, 13.7% and 5.2% relative reductions in the number of patients obtaining blastocysts, euploid blastocysts, LBs, supernumerary blastocysts without an LB and surplus blastocysts after an LB, respectively. LIMITATIONS, REASONS FOR CAUTION: Gestational and perinatal outcomes were not assessed, and a cost-effectiveness analysis is missing. Moreover, we encourage other groups to investigate this topic with different culture and biopsy protocols, as well as in different clinical settings and regulatory contexts. WIDER IMPLICATIONS OF THE FINDINGS: In view of the increasing personalization and patient-centeredness of IVF, whenever allowed from the local regulations, the choice to culture embryos to Day 7 should be grounded on the careful evaluation of couples' reproductive history. Patients should be aware that Day 7 blastocysts are less competent than faster-growing ones; still, poor prognosis couples, couples less compliant toward other attempts in case of a failure and couples wishing for more than one child, may benefit from them. AI tools can help improving the generalizability of the evidence worldwide. STUDY FUNDING/COMPETING INTEREST(S): This study did not receive any funding. I.E., A.B.M. and I.H.-V. are employees of Fairtility Ltd. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cimadomo D, Soscia D, Casciani V, et al. How slow is too slow? A comprehensive portrait of Day 7 blastocysts and their clinical value standardized through artificial intelligence. Hum Reprod. 2022. PMID: 35459944. doi:10.1093/humrep/deac080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。